GL Pharm Tech
지엘팜텍 · 204840
Consumer Staples Staples Retail · KOSDAQ
Market cap US$51.4M (₩71B)
Overview
GL Pharm Tech makes and markets prescription and over-the-counter medicines, including treatments for nerve pain, stomach ulcers, inflammation, and hormonal conditions such as contraceptives, supplied to hospitals, pharmacies, and other healthcare buyers in Korea.
Listed on KOSDAQ, Korea's tech and small-cap exchange, the company operates across two main activities: distributing finished medicines under its own marketing arm and manufacturing them through its consolidated subsidiary, GL Pharma. A meaningful share of its revenue comes from licensing its improved-drug formulations to domestic and overseas pharmaceutical companies and collecting ongoing royalties on their sales.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$18.9M
- FY2024US$18.9M
- FY2025US$25.6M
Operating profit
- FY2023−US$2.3M
- FY2024−US$1.3M
- FY2025US$194.5K
Net income
- FY2023−US$2.7M
- FY2024−US$1.7M
- FY2025US$9.1K
Key ratios (FY2025)
Why it matters
GL Pharm Tech's consolidated subsidiary, GL Pharma, handles the manufacturing side of the business, while the parent focuses on research-and-development services and sales marketing.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?